psoriasis

'Forgotten' systemic drugs for psoriasisWith the recent discoveries of immunologic pathways leading to psoriasis, clinicians are likely to discount older general immunosuppressive agents in favor of newer larger molecules like biologics that provide better targeted therapy.
August Clinical Considerations for NPs, PAsIn this edition of Clinical Considerations, we examine the benefits of the dermatoscope, caring for psoriasis patients, and treating AK patients.
Biosimilar drugs appear comparable to brand-name counterpartsSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments.
Interventions to improve quality of life for patients with psoriasis and psoriatic arthritis
Interventions to improve quality of life for patients with psoriasis and psoriatic arthritisThe goal of this activity is to educate pharmacists and pharmacy technicians about pharmacist interventions in improving the quality of life for patients with psoriasis and psoriatic arthritis. Readers will also gain knowledge about available options for treatment, adverse effects, risks, and benefits.
Beyond the plaqueThere’s good evidence to suggest dermatologists who assess psoriasis patients should look beyond the plaques on the skin and consider not just the increased risk to the joints, but also the heart, mind and more.
The oral pipeline for psoriasisOral options in the pipeline for psoriasis show promise.
Ixekizumab effective psoriasis treatment through 60 weeksResults from three phase 3 trials, suggest ixekizumab (Talz, Eli Lilly & Company) is effective through 60 weeks of treatment among patients with moderate-to-severe plaque psoriasis.
New research focuses on B lymphocytes in psoriasisResearchers at the University of Würzburg in Bavaria, Germany, are focusing their psoriasis research on a cell type that has received little attention in connection with the skin disease: B lymphocytes.
Insurers make prescribing biologics difficultA new study suggests that insurance coverage of biologics for psoriasis is becoming more challenging. The need for prior authorization is increasing, as are the average time from prior authorization submission to coverage decisions and prior authorization denial rates.
Making strides in support for psoriasis patientsThe National Psoriasis Foundation seeks support for initiatives that will provide better access for psoriasis patients to effectively treat their disease.